Ashok Amin - Co-Editor-in-Chief - Journal of Molecular Signaling Updates

Dr. Ashok Amin, has been on the Faculty of the Dept. of Biomedical Engineering at Virginia Tech since 2007. He was the Vice President of Research at Carilion Clinic and Advaxis Inc. He procured a PhD in Microbiology from Dept. of Microbiology and Biotechnology, Baroda, India.   He was also trained in Bio-organic chemistry at Bhabha Atomic Research Center, India as part of his PhD thesis. He later joined as a National Institute Health [USA]-Sponsored post-doctoral fellow in Immunology at New York University [NYU] in 1986, after which he led the Research in the Department of Rheumatology as Director of Research and Associate Professor of Pathology and Medicine at NYU’s Hospital for Joint Diseases [HJD].  

He has been selected for several distinguished awards such as: Fellow of the Department of Atomic Energy, India; Young Investigator Award from the National Institute of Health, USA. Distinguish Investigator from the Dept. of Medicine, NYU; Tibor Fabian Award for Excellence in Science; Young Scholar Award--Arthritis Foundation; USA and several others.

He has been actively involved with the growth of several organizations. At NYU’s HJD he led Rheumatology Research. The department at HJD advanced among the top five hospitals for Clinical Rheumatology and Education in USA during Dr. Amin’s tenure. He was the founding Vice President of Research for Carilion Clinic which has a total operational budget of over one billion with approximately million patient visits. He established research centers and laboratories of translational research with resounding success He has been a member of the Management Council at NYU, Carilion Clinic, Virginia College of Medicine, and Advaxis Inc. This includes about 20 academic and administrative appointments. He has been an invited speaker or chairperson at about 60 international scientific meetings and also presented plenary lectures on cutting edge research in several International Arthritis Meetings.

He has acted as a collaborator or consultant to 17 different pharmaceutical companies, including Schering Plough (NYSE: MRK), Dupont-Merck, Yamanouchi Pharmaceuticals, Ranbaxy Laboratories, Ltd (OTC: RBXLY), and Forest Laboratories (NYSE: FRX).

He has served on over 27 editorial boards or as an ad hoc reviewer for many leading scientific publications includingJournal of Immunology,Nature,The New England Journal of Medicine,ScienceandThe Wall Street Journal. He has acted as investigator or administrator on over 40 clinical trials, obtained 22 patents, and authored 90 peer-reviewed journal articles, reviews and book chapters. He has led several international multidisciplinary research teams and created scalable and high impact models for commercialization of intellectual property with international partners and venture capital firms. His research papers are highly cited for break through research. For example his papers in Proc. Natl. Acad. Sci. USA led to patents in drug development. Dr. Amin's team discovered the drug ORACEA(R) (doxycycline, USP), which is currently being marketed by Galderma for the treatment of Rosacea. It has a market cap of over $200 million a year. His other papers include areas of translational and interdisciplinary genomics in human diseases such as arthritis, cancer and inflammatory diseases. He exhibits a track record in successful academic-pharmaceutical corporation drug discovery and development research projects. Dr. Amin has trained and guided over 30 students to excellent careers and procured over 50 research grants and contracts to propel his research in microbiology, biochemistry, immunology, genomics, in cancer and inflammatory diseases.

copyrrightCreative Commons LicensePayza1cross